AIM: Aim of this study is to determine the efficacy of intrathecal baclofen treatment in the medically intractable severely disabling spasticity and present the challenges encountered during pump implantation surgery on these patients.
INTRODUCTION
Spasticity is the consequence of several clinical conditions including cerebral palsy, brain injury, spinal cord injury, multiple sclerosis, aneurysm bleeding, and some other neurological disorders 1 . Spasticity can be described as the muscle stiffness and spasm that is accompanied by involuntary jerking and sometimes pain 2 . When the spasticity is generalized and it is severe, the patient is usually immobilized and has the propensity to very low quality of life and poor care. Grading of the spasticity is achieved by applying the Modified Ashworth Spasticity Scale (MASS) in order to gain a standardized objective determination of the spasticity. It also helps measuring the efficacy of the treatment modalities in the follow-up. Practically, MASS measures resistance during passive softtissue stretching. It is done in the supine position. Since spasticity is velocity dependent, the joint or the muscle group subject to testing is moved at the speed of gravity. After establishing an accurate diagnosis of spasticity, treatment options are assessed.
Therapeutic options for these cases include oral medications, nerve blocks, destructive neurosurgical procedures and intrathecal administration of antispastic agents 3 . Baclofen has been used orally to treat spasticity but its systemic side effects limit the dose a patient can take. It is a synthetic analog of gama aminobutyric acid (GABA) and acts by stimulating the GABA type B receptor subtype in the central nervous system. In 1984 Penn and Kroin introduced intrathecal administration of baclofen to treat spasticity and it has been used in patients who had developed resistance to or could not tolerate orally administered antispasmodic drugs 4 . In the last decade, the use of baclofen delivered intrathecally via an implanted programmable pump has become the principal treatment in the management of spasticity [5] [6] [7] . Initially, a trial injection of intrathecal baclofen (ITB) has been applied and patient's response to the administered dose of the drug is observed. The decision to implant a pump is established on a positive response; that is at least two-point decrease in Modified Ashworth Spasticity Scale (MASS) and absence of the unwanted adverse effects 8 .
We intented to emphasize the difficulties in baclofen pump implantation surgery and share our experience in the management of severe spasticity cases.
MATERIALS AND METHODS

Patients
Patients who attended the Gülhane Military Medical Academy, Haydarpaşa Teaching
Hospital and underwent intrathecal baclofen pump (ITP) implantation surgery at the neurosurgery department between 2012-2015 were recruited from the medical records of the clinic. The study design was approved by the ethical committee of the GATA Haydarpaşa Teaching Hospital and conforms to ethical standards as described in the Declaration of Helsinki. The same team of a neurologist, physiatrist, and a neurosurgeon obtained MASS scores for each individual at their follow-up visits ( Table 1) . 22 of the patients met the following criteria for inclusion in the study:
1) ITP placement surgery;
2) Non-ambulant patients with severe spasticity (MASS 3-4), impairing function and personal care;
3) At least 3 preoperative assessments free from antispastic drugs; 4) Available follow-up visits at the end of the first, third and sixth months postoperatively.
Pump Implantation
When an indication of ITP implantation has been decided in case of positive trial response, a pump (SynchroMed II, Medtronic, Minneapolis, USA) was implanted by the first author (HŞ) in the subcutaneous pocket in the lower quadrant of the abdomen on the left side and connected to the intrathecal catheter under general anesthesia (Figures 1 and 2 ). Pumps with 20 ml volume capacity were implanted to the patients in the pediatric group, and 40 ml volume capacity pumps were preferred for the adult patients. The level where the tip of the catheter would be left was determined according to the involvement of neck and the upper extremities. When percutaneous catheter insertion was not successful despite fluoroscopic guidance, this position let us switch to direct catheter placement in the intrathecal space via partial hemi-laminectomy at the same level where percutaneous placement of the catheter was intended. We usually performed partial hemilaminectomy at the lumbar 2-3-interlaminar space. Once the patient is anesthetized and positioned appropriately, we believe that the patient deserves pump implantation in any available way and it was mentioned in the informed consent that is routinely obtained from the patients or their families.
The baclofen start doses are mentioned in 
Statistical Analysis
Raw data were analyzed using SPSS statistics packet program version 20.0 for Mac.
Minimum value, maximum value, mean, and standard deviation (sd) were used to define data. Postoperative MASS scores were compared to that of the preoperative values using the Wilcoxon Signed-Rank test. P-values less than 0.05 were considered statistically significant (p < 0.05).
RESULTS
Eight of the patients were at pediatric age (mean age 10.6 years, ranged from 7 to 14 years) and they developed spasticity due to CP. They were all non-ambulant and families had great difficulty in care.Visual analog scale (VAS) scoring could not be applied to 9
patients.The 14 adult patients (5 females, 9 males) had a mean age of 41.5 years (range: 23-63 years). All of them were not ambulant and unable to sit in awheelchair. The cause of spasticity in the series was MS in 7 cases, spinal cord injury in 3, CP in 8, transverse myelitis in 1, aneurysmal subarachnoid hemorrhage in 2, and traumatic brain injury in 1 patient ( Table 1) . Twenty of the patients were quadriplegic and 2 patients with MS were paraplegic. All the patients ceased oral medications at least three days before the trial day if applicable and then underwent a prepump implantation trial of ITB with 50-µg bolus delivered by lumbar puncture and followed by tone assessments over 6 to 8 hours. Records revealed that we had to administer a fifty percent increased second baclofen dose to only 3 patients during the prepump baclofen benefit trials in the next day. Pediatric group received ITB (25 µg) at the dose that was half the adults had received. Reduced mean MASS of at least 2 points was taken as positive response to trial. Again the patients ceased antispastic oral drugs three days before surgery and the same physiatrist and a neurologist/pediatric neurologist evaluated them the day before implantation of the ITP free of oral antispastic medications.
The catheter was placed (between C7-T10 level) through a percutaneous technique into the lumbar subarachnoid space in 18 of the 22 patients. Four of the patients with CP (2 adult and 2 children) had severe spinal rotation and scoliosis, therefore the 16 T-gauge Tuohy introducer needle could not be inserted in the intrathecal space and we had to place the catheter after performing a partial hemi-laminectomy in the lateral decubitus position.
Positioning the patients was a challenge but the operation room team got used to managing the condition after several cases. Induction of the anesthesia dissolved spasticity but muscle contractures remained. Hip motion was usually restricted so in order to give the lateral decubitus position on the right side, we fed the whole body with silicone pads to release the right hip and shoulder and supported the left leg over the right leg with pillows and fixed the body in lateral position. We used anterior and posterior supports for chest and a posterior support at the upper thigh level. Therefore, adductor muscles of the hips with contracture did not encounter violation and extra injury (Figures 1and 2) .
Laminectomy alone was not a reason for a longer hospital stay in any of the patients.
Patients did not suffer extra pain because of the laminectomy procedure as they are on analgesic medication for the pump pocket incision site.
Follow-up examinations were arranged in the end of first, third and sixth months. Mean follow-up time of the overall group was 14.18 months. Owing to the continuous delivery of a constant dose of ITB, all of the patients got a steady relief of spasticity. All the patients enrolled in the study were severely disabled and immobile at the beginning (20 spastic quadriplegic, 2 spastic paraplegic). Mean MASS score of the patients improved from 3.59 to 1.32 (Table 1) . P value was lower than 0.001, representing a highly significant difference (Table 2) . Mean VAS score of the available 13 patients was 9.3 in the preoperative assessment and it regressed to 4 at the 3 rd month evaluation in the postoperative follow-up. Adult group received an average of 80.8 µg daily baclofen dose, where the pediatric group received 81.4 µg daily baclofen, indicating that there was not a significant difference between the adult and pediatric group regarding the dose they received. MS patients had remarkable benefit from the baclofen treatment. We recorded at least two points of MASS score reduction. 5 of 7 MS patients were able to walk in the end of three months following appropriate physical training. Patients with CP were able to sit in the wheel chair following ITB treatment but they were not able to walk. Since they were not coordinating, they could receive only passive physical training to regain the appropriate range of motion of their joints. Nevertheless, caregivers or families who were attending these patients were satisfied with the ease of care they had after ITB treatment. Further studies including electrophysiological and mental tests should be performed for these patients to measure any improvement in cognitive function.
In the postoperative follow-up period we did not encounter any complications in our series other than one patient who was referred back to our clinic with fluctuating swellings in the pump area and lumbar incision site. He was a 23-year-old man with cervical spinal cord injury who presented with spastic tetraplegia. ITP implantation surgery was planned, but percutaneous catheter placement was unsuccessful, so we performed partial hemilaminectomy and transduced the catheter under direct visualization at the lumbar 3 rd vertebra level. We revised the pump and found that the pump and the catheter system were intact. CSF was entrapped in the pump pocket and in the lumbar subcutaneous pouch (Fig   3) . Lumbar fascia at the laminectomy site was tight but catheter required anchoring and tightening sutures were put where it penetrated the fascia. We reimplanted the pump in its pocket and postoperative course was uneventful and he did not experience any other complications (Fig 3) . 
DISCUSSION
We enrolled 22 patients with severe spasticity in the study that underwent baclofen pump implantation surgery. Overall MASS scores significantly improved and the procedure enhanced quality of life of all patients. 9 over 22 patients were not eligible for VAS score measurement. However, 13 patients had significant pain relief.
In the case of disabling spasticity, oral medication has been the first choice because of easy administration route. Oral baclofen is widely used, however the untoward effects of oral baclofen such as sedation, respiration problems and muscular weakness in higher doses, limit its use. It also modulates pain due to its direct effect on GABA receptors. Though not all patients with spasticity benefit from this treatment, it allows for a successful management of the spasticity of the patient 7 . Inhibition of spasticity increases mobility and makes the patient more liable to benefit from physical treatment 9, 10 . Overall benefit is increase in quality of life of the patient and caregivers, as well 11, 12 . However, as in most of the surgical interventions involving implantation of a catheter and pump as foreign bodies, certain complications including infection, hardware malfunction, displacement of the catheter or the mechanical device, rejection of the system by the host, patient's intolerance to system and uncooperative patient profile, and alterations in response to medication because of individual features may be encountered. Inadvertent effects of the medication used via such closed systems are the most challenging of all since the administered drug has pretty narrow therapeutic window. Fluctuations in dose may not be tolerated because both withdrawal and overdose of intrathecally-administered baclofen may be potentially life threatening and necessitate intensive care 13 . Although these complications are rare if certain practice guidelines are followed, clinicians should be prepared to recognize and treat them timely. Abrupt withdrawal of ITB can result in high fever, drowsiness and sometimes coma, return of spasticity, muscle rigidity, and in rare cases even death. An acute massive overdose can cause coma; less severe overdoses can cause drowsiness, lightheadedness, respiratory depression, seizures, hypotonia, and loss of consciousness.
The most prominent side effect is hypotonia, and can be addressed in most cases by adjusting the rate of administration 11, 14, 15 .
A steady CSF concentration of the drug allows to generate the same effects that of oral high dose administration of baclofen except that untoward side effects including sedation, respiration problems and muscular weakness will be avoided. It takes several weeks to months to set to the desired effects and dose relation.
In our series, following a series of incremental adjustments, dosage remained stable after three months. That is ideal to find out how the patient will feel like when the drug reached therapeutic concentrations, because some patients require doses above or below the designated range and even some patients experience drug toxicity within the therapeutic range.
Actually, during classical trial injections to the patient, incremented dosage is administered and takes 3 days to the longest, and does not need hospitalization unless the patient has a special condition that necessitates so. In the severely disabled group of patients, we did not have to readminister a second or third incremented baclofen dose to observe the benefit of the patients, because they all had significant relief following the initial trial dose. The next step for these patients remained dose adjustments following the implantation of the pump.
Overall, continuous intrathecal administration of the baclofen to evaluate its systemic and functional effects can be considered as a helpful method as mentioned by some authors, 16 but we believe it would put extra burden on both the patient and the hospital by hospitalizing and using another trial pump for several days. After coming to a consensus on the implantation of the baclofen pump, all the patients were operated and a catheter was placed in the intrathecal space either via percutaneous route or via partial hemilaminectomy in the right decubitus position usually at the 2-3 or 3-4 interlaminar spaces. In severely disabled patients, usually the spinal column is anatomically deformed and intervertebral space does not allow the Tuohy needle to pass through. Since the patient had general anesthesia, we did not give up the implantation procedure in any of the patients and performed the laminectomy to place the catheter in the subarachnoid space. Sometimes the dural compression and arachnoid synechias due to the interrupted CSF turnover do not let CSF to flow through the Tuohy needle although you might be in the thecal sac. After transducing the catheter into the subarachnoid space and placing the tip in the desired level, CSF flow is observed. After experiencing a CSF collection in the subcutaneous pouch, we began passing the catheter through the fascia by penetrating it at the intact site to prevent CSF fistula.
In order to measure the goal achievements after implantation, patients (when available), caregivers, and the family were asked to rate whether in their terms the goals were achieved satisfactorily, or not. Better seating, feeding, improved sleep patterns, mood, eased provision of care, decreased pain were expressions of satisfaction and they were set as a simple statement implying overall benefit from the procedure 17 . Our results were also consistent with the current literature. Current data indicate that ITB therapy effectively and significantly reduces severe spasticity in non-ambulatory patients caused by various reasons 7, 18 . This striking success of intrathecal baclofen use might be attributed to several factors including appropriate patient selection, education about realistic expectations, and careful dose titration in time. To the benefit of the patients, physiatrists are also involved in the decision-making and postoperative assessment period, so early involvement of rehabilitation therapists in the procedure contributes to maximize clinical outcome.
Caregivers report muscle relaxation alone, as a positive benefit of the therapy but further physical treatment is needed. While the patients are under the effect of baclofen, determining the range of motion of each joint and the muscles with intractable contracture, which are candidates for surgical release is another important issue to deal with. After reaching the physiological limits of the functioning muscles, additional treatment modalities might be considered. After all, when the patients are anesthetized and myorelaxant agents are administered, you can evaluate the limits of physiological motion and contractures at the extremities of these patients. The main goal is gaining the largest span of independent active, and passive movement of the extremities and the trunk. Since all of the patients in our series were dependent to others in terms of hygiene, feeding, positioning, and ambulation, this also brought ease of care for the caregivers. After the intrathecal baclofen treatment, MASS scores of the patients improved significantly. As the restriction of the disabling spasticity is decreased gradually 5 patients began using their hands for grasping and 3 patients began ambulating in the house with an assistive device following intensive physiotherapy. Another benefit of the ITB therapy as reported previously was improvement in nutritional status, particularly in the pediatric patient group 19 . They began putting on weight in the end of the second month, because first, they could swallow easier as mentioned by the parents or caregivers; second, their health conditions improved and they had less infectious problems due to decreased pulmonary aspiration. In accordance with the improvement of the MASS scores, we found out pain relief in 13 of the patients and it was quantified with VAS assessments (Table 1) . Four of the patients in the pediatric group had improved mood and decreased yelling and crying episodes as noted by their parents. Pediatric neurologist ceased sedative medications for these patients.
Some authors reported impairment in the spinal column alignment and worsening of the scoliosis in some of the patients who received the ITB treatment after a certain period of time 20, 21 . Our overall impression from our study is that the ITB therapy does not interfere with the underlying natural tendency to develop scoliosis for the most severely disabled children. Likewise, we also have observed that the number of the orthopedic surgical interventions did not increase related to the ITB therapy, in the contrary, both the orthopedics and the families had tendency to reconsider surgical intervention 22, 23 . Because it is rational that if the patient is found relaxed compared to the prepump assessments, one may cancel the preplanned operation for an individual, while he can identify new potential of benefit and consider orthopedic intervention 18 . The most important question of the issue here is if early onset of ITB therapy will reduce contractures and yield more definite improvements in terms of ambulation, and functionality. Besides ease of access to physiotherapy and insurance coverage, consistency of the patients and their families to a regular based training sessions and home training takes the first place in the improvement of these patients, thereafter 24 .
CONCLUSIONS
We retrospectively assessed the patients whom we operated on and implanted ITP in a select group of non-ambulant patients with severely disabling spasticity. Detailed examination of the records revealed that all had satisfactory outcomes in the minimum 6 months of follow up. Although spinal structural deformities of the severely disabling spastic patients are a challenge in the placement of the catheter, it does not totally restrict surgical intervention. Determining rationale goals preoperatively is the core issue, and is followed by patient and family consistency to treatment. Therefore, while planning this treatment, realistic balance of likely gains and possible losses should be carefully explained to the families and patients if applicable. We observed that families and physiatrist got excited about involving them in physiotherapy with the hope of further improvement. ITB usually produced many other improvements apart from the programmed aims and beyond the expectations of the families or caregivers. ITB therapy apparently increases quality of life and increases functional outcome. So, as a surgical treatment modality, select patients should be given this chance at the earliest period of their lifetime disability. One patient experienced CSF collection in the pump pocket and the spinal incision site. We revised the pockets and the pump was reimplanted after ensuring that the system was intact. The fascia that was damaged by the Tuohy needle during our attempts to place the catheter by percutaneous technique was the route of the CSF fistula into the pouch and we repaired it with several stiches and we anchored the catheter by a pursestring suture to the fascia.
